NCT05858619RecruitingPhase 4
Molecular Signatures of Cutaneous Dupilumab Response
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 4 May 2023
- Start date
- 1 Feb 2023
- Primary completion date
- 1 Feb 2028
- Lead sponsor
- University of California, San Francisco
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT05858619
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 15
- From 1 Feb 2023 to the primary completion date, 1 Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known parasitic infection -
Other
- Known pregnancy
- Known immunodeficiencies
Who the study is looking for
- 18 years of age or older
- atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.